BDBM305347 US10144734, Example 363::US10881652, Example 363

SMILES: CCOc1cc(-c2ccc(nc2)N2C[C@H](N)[C@H](C2)Oc2ccc(OC)cn2)c2c(cnn2c1)C#N

InChI Key: InChIKey=FNDLMBPWJRRKND-VXKWHMMOSA-N

Data: 6 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 305347   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens (Human))	BDBM305347 (US10144734, Example 363 | US10881652, Example 363) Show SMILES CCOc1cc(-c2ccc(nc2)N2C[C@H](N)[C@H](C2)Oc2ccc(OC)cn2)c2c(cnn2c1)C#N |r| Show InChI InChI=1S/C25H25N7O3/c1-3-34-19-8-20(25-17(9-26)11-30-32(25)13-19)16-4-6-23(28-10-16)31-14-21(27)22(15-31)35-24-7-5-18(33-2)12-29-24/h4-8,10-13,21-22H,3,14-15,27H2,1-2H3/t21-,22-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.5	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...				US Patent US10144734 (2018) BindingDB Entry DOI: 10.7270/Q2251M8C
					More data for this Ligand-Target Pair
RET kinase mutant (V804M) (Homo sapiens (Human))	BDBM305347 (US10144734, Example 363 | US10881652, Example 363) Show SMILES CCOc1cc(-c2ccc(nc2)N2C[C@H](N)[C@H](C2)Oc2ccc(OC)cn2)c2c(cnn2c1)C#N |r| Show InChI InChI=1S/C25H25N7O3/c1-3-34-19-8-20(25-17(9-26)11-30-32(25)13-19)16-4-6-23(28-10-16)31-14-21(27)22(15-31)35-24-7-5-18(33-2)12-29-24/h4-8,10-13,21-22H,3,14-15,27H2,1-2H3/t21-,22-/m0/s1	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22.7	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...				US Patent US10144734 (2018) BindingDB Entry DOI: 10.7270/Q2251M8C
					More data for this Ligand-Target Pair
RET kinase mutant (G810R) (Homo sapiens (Human))	BDBM305347 (US10144734, Example 363 | US10881652, Example 363) Show SMILES CCOc1cc(-c2ccc(nc2)N2C[C@H](N)[C@H](C2)Oc2ccc(OC)cn2)c2c(cnn2c1)C#N |r| Show InChI InChI=1S/C25H25N7O3/c1-3-34-19-8-20(25-17(9-26)11-30-32(25)13-19)16-4-6-23(28-10-16)31-14-21(27)22(15-31)35-24-7-5-18(33-2)12-29-24/h4-8,10-13,21-22H,3,14-15,27H2,1-2H3/t21-,22-/m0/s1	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	35	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...				US Patent US10881652 (2021)
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens (Human))	BDBM305347 (US10144734, Example 363 | US10881652, Example 363) Show SMILES CCOc1cc(-c2ccc(nc2)N2C[C@H](N)[C@H](C2)Oc2ccc(OC)cn2)c2c(cnn2c1)C#N |r| Show InChI InChI=1S/C25H25N7O3/c1-3-34-19-8-20(25-17(9-26)11-30-32(25)13-19)16-4-6-23(28-10-16)31-14-21(27)22(15-31)35-24-7-5-18(33-2)12-29-24/h4-8,10-13,21-22H,3,14-15,27H2,1-2H3/t21-,22-/m0/s1	PDB MMDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.5	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...				US Patent US10881652 (2021)
					More data for this Ligand-Target Pair
RET kinase mutant (V804M) (Homo sapiens (Human))	BDBM305347 (US10144734, Example 363 | US10881652, Example 363) Show SMILES CCOc1cc(-c2ccc(nc2)N2C[C@H](N)[C@H](C2)Oc2ccc(OC)cn2)c2c(cnn2c1)C#N |r| Show InChI InChI=1S/C25H25N7O3/c1-3-34-19-8-20(25-17(9-26)11-30-32(25)13-19)16-4-6-23(28-10-16)31-14-21(27)22(15-31)35-24-7-5-18(33-2)12-29-24/h4-8,10-13,21-22H,3,14-15,27H2,1-2H3/t21-,22-/m0/s1	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22.7	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...				US Patent US10881652 (2021)
					More data for this Ligand-Target Pair
RET kinase mutant (G810R) (Homo sapiens (Human))	BDBM305347 (US10144734, Example 363 | US10881652, Example 363) Show SMILES CCOc1cc(-c2ccc(nc2)N2C[C@H](N)[C@H](C2)Oc2ccc(OC)cn2)c2c(cnn2c1)C#N |r| Show InChI InChI=1S/C25H25N7O3/c1-3-34-19-8-20(25-17(9-26)11-30-32(25)13-19)16-4-6-23(28-10-16)31-14-21(27)22(15-31)35-24-7-5-18(33-2)12-29-24/h4-8,10-13,21-22H,3,14-15,27H2,1-2H3/t21-,22-/m0/s1	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	35	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...				US Patent US10144734 (2018) BindingDB Entry DOI: 10.7270/Q2251M8C
					More data for this Ligand-Target Pair